The Predictive Value of HER2 in Breast Cancer

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Oncology

• Publication date

  2001-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000055405PMID 11694791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?

  2004cited by this paper
• Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.

  2002cited by this paper
• 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

  2001cited by this paper
• Role of Herceptin® in Primary Breast Cancer: Views from North America and Europe

  2001cited by this paper
• Testing for HER2 Status

  2001cited by this paper
• Developments in chemotherapy of breast cancer

  2000cited by this paper
• Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

  2000cited by this paper
• HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?

  2000influential reference
• The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.

  2000influential reference
• Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

  2000cited by this paper
• Assessment of HER2 status in breast cancer: why, when and how?

  2000cited by this paper
• First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody)

  2000cited by this paper
• c‐erbB‐2 over‐expression in amplified and non‐amplified breast carcinoma samples

  1999cited by this paper
• Effect of c‐erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

  1999cited by this paper
• The c-erbB-2 Oncogene Amplification by Competitive PCR in Aneuploid Cell Clones Flow Sorted from Breast Cancer Samples

  1999cited by this paper
• Breast cancer trends of black women compared with white women.

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

  1999cited by this paper
• First MAb approved for treatment of metastatic breast cancer.

  1999cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

  1998cited by this paper
• HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

  1998cited by this paper
• p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• [Prognostic factors in breast cancer].

  1998cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.

  1997cited by this paper
• Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

  1996cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996cited by this paper
• Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

  1995cited by this paper
• Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.

  1995cited by this paper
• Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

  1995cited by this paper
• c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.

  1995cited by this paper
• College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee.

  1995cited by this paper
• Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.

  1994cited by this paper
• The biology of erbB-2/neu/HER-2 and its role in cancer.

  1994cited by this paper
• Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy.

  1993cited by this paper
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

  1992cited by this paper
• HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

  1992cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

  1992cited by this paper
• Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

  1992cited by this paper
• Prognostic factors in breast cancer.

  1992cited by this paper
• Prognostic factors in breast cancer.

  1992cited by this paper
• Breast cancer prognostic factors: evaluation guidelines.

  1991cited by this paper
• A Hitchhiker’s Guide to the NIEHS Strategic Plan

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Preventive, Personalized, and Precision Medicine and Biomarkers for Breast Cancer Diagnosis: Artificial Intelligence Framework

  2025cites this paper
• Photoimmunotherapy of HER2-expressing Breast Cancer Cells

  2024cites this paper
• Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer

  2024cites this paper
• Paraneoplastic Amaurosis With Positive Anti-Physician Antibody In A Patient With Breast Cancer: A Case Report.

  2023cites this paper
• A systematic review of multimodal application of quantum dots in breast cancer diagnosis: Effective parameters, status and future perspectives

  2023cites this paper
• Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis

  2023cites this paper
• Multimodal analysis of genome-wide methylation, copy number aberrations, and end motif signatures enhances detection of early-stage breast cancer

  2023cites this paper
• Breast Cancer Presenting As Onconeural Antibody Negative Opsoclonus-Myoclonus Syndrome

  2022cites this paper
• Integrating biology into clinical trial design

  2022cites this paper
• Applications of Machine Learning in Disease Pre-screening

  2021cites this paper
• American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians.

  2021cites this paper
• Anti-Ri-associated paraneoplastic ophthalmoplegia-ataxia syndrome in a woman with breast cancer: a case report and review of the literature

  2020cites this paper
• Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage

  2020cites this paper
• Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease?

  2019cites this paper
• Can enhancement types on preoperative MRI reflect prognostic factors and surgical outcomes in invasive breast cancer?

  2019cites this paper
• COGNITIVE AFFECTIVE SYNDROME IN ANTI-YO CEREBELLAR DEGENERATION, Le May and Dent

  2018cites this paper
• Genetic Testing for Breast Cancer Gene Expression Prognosis Assay

  2018cites this paper
• A STUDY ON FUTURE TRENDS OF DATA MINING FOR PREDICTION OF CANCER

  2018cites this paper
• Evidencia sobre la expresión de Her-2 en la enfermedad de Paget Extramamaria

  2018cites this paper
• Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade

  2018cites this paper
• Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.

  2018cites this paper
• A 14‐Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma

  2018cites this paper
• The Dawning of Translational Breast Cancer: From Bench to Bedside.

  2017cites this paper
• Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer

  2017cites this paper
• Stratifying Cancer Therapies by Molecular Interactions and Imaging

  2017cites this paper
• Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.

  2017cites this paper
• Combinatorial Protein Engineering Of Affibody Molecules Using E. Coli Display And Rational Design Of Affibody-Based Tracers For Medical Imaging

  2017cites this paper
• Uloga patologa u dijagnostici i terapiji pacijenata s karcinomom dojke

  2016cites this paper
• The role of the pathologist in diagnosis and therapy of the breast cancer patients

  2016cites this paper
• Evaluation of the association between HIF-1α and HER-2 expression, hormone receptor status, Ki-67 expression, histology and tumor FDG uptake in breast cancer

  2016cites this paper
• Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England

  2016cites this paper
• An investigation into the pathophysiology of breast cancer-related lymphoedema

  2015cites this paper
• Identification and Functional Validation of Novel Ligands of PPAR gamma - Therapeutic Implications for Breast Cancer

  2015cites this paper
• Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine.

  2015cites this paper
• Quantum Dots Targeted to VEGFR2 for Molecular Imaging of Colorectal Cancer

  2015cites this paper
• Endocrine resistance in breast cancer--An overview and update.

  2015cites this paper
• Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics

  2015cites this paper
• Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

  2014cites this paper
• Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

  2014cites this paper
• ScFv‐Decorated PEG‐PLA‐Based Nanoparticles for Enhanced siRNA Delivery to Her2+ Breast Cancer

  2014cites this paper
• HER2 as a Predictive Factor for Successful Neoadjuvant Anthracycline Chemotherapy of Locally Advanced and Early Breast Cancer

  2014cites this paper
• Models Predicting Effects of Missense Mutations in Oncogenesis

  2014cites this paper
• Breast-Cancer Subtyping in Clinical Practice: Clinicopathologic Features and Outcomes

  2014cites this paper
• Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study

  2014cites this paper
• Intracellular Delivery of ERBB2 siRNA and p53 Gene Synergistically Inhibits the Growth of Established Tumor in an Immunocompetent Mouse

  2014cites this paper
• Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease

  2013cites this paper
• Understanding the impact of estrogens in mammary gland formation using an in vitro three-dimensional model

  2013cites this paper
• Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment.

  2013cites this paper
• Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.

  2012cites this paper
• Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.

  2012cites this paper
• The miR-200 and miR-221/222 microRNA Families: Opposing Effects on Epithelial Identity

  2012cites this paper
• Profiling signalling pathways in formalin‐fixed and paraffin‐embedded breast cancer tissues reveals cross‐talk between EGFR, HER2, HER3 and uPAR

  2012cites this paper
• Animal Models for Breast Cancer Prevention Research

  2012cites this paper
• PREDICTORS OF THE EFFICIENCY OF RADIATION/CHEMORADIATION TREATMENT FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

  2012cites this paper
• Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer

  2012cites this paper
• Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review).

  2011cites this paper
• Discovery of New Molecular Subtypes in Oesophageal Adenocarcinoma

  2011cites this paper
• Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action

  2011cites this paper
• Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.

  2011cites this paper
• Studies on molecular and signaling pathways of epithelial-mesenchymal transition in canine mammary tumor

  2011cites this paper
• Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.

  2011cites this paper
• Use of formalin-fixed and paraffin-embedded tissues for diagnosis and therapy in routine clinical settings.

  2011cites this paper
• An Extensive Survey on Artificial neural Network Based Cancer Prediction Using Soft-Computing Approach

  2011cites this paper
• Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches

  2011cites this paper
• Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues

  2010influential citation
• MOLECULAR CHARACTERISATION OF THE HER2-TOP2A AMPLICON IN BREAST CANCER

  2010cites this paper
• Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma: Comparison With FISH and Assessment of Interobserver Reproducibility

  2010cites this paper
• Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues.

  2010cites this paper
• Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays

  2010cites this paper
• Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens

  2010cites this paper
• Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine.

  2010cites this paper
• Surgical Treatment for Women with Breast Cancer: Do Randomized Clinical Trials Represent Current Medical Practices?

  2010cites this paper
• Amplification and prognostic efficiacy of her-2 in c-erbb-2 score 2 breast carcinomas

  2010cites this paper
• AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.

  2009cites this paper
• In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice.

  2009cites this paper
• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  2009cites this paper
• Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.

  2009cites this paper
• Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study

  2009cites this paper
• Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.

  2009cites this paper
• Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.

  2009cites this paper
• Hypoxia and Hypoxia-Inducible Factors in Normal and Malignant Breast Epithelium

  2008cites this paper
• The European cancer informatics landscape: Challenges for the biomedical informatics community

  2008cites this paper
• Changes of Coregulators, MAP Kinase Activity and p27/kip1 with Estrogen or Antiestrogen Treatment in Breast Cancer Cell Line

  2008cites this paper
• Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts

  2008cites this paper
• Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes.

  2008cites this paper
• “The European cancer informatics landscape: Challenges for the biomedical informatics community”

  2008cites this paper
• The influence of tumour progression on serum concentration of HER2 receptor extracellular domain and metalloproteinase 9 in patients with uterine cervical cancer

  2008cites this paper
• Mammakarzinom im lokalisierten Stadium – Strategien für die systemisch-adjuvante Therapie

  2008cites this paper
• Role of AIB1 for Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells

  2008cites this paper
• [Early-stage breast cancer - strategies for adjuvant systemic therapy].

  2008cites this paper
• Signal Transduction in Transgenic Mouse Models of Human Breast Cancer—Implications for Human Breast Cancer

  2008cites this paper
• Targeted Therapy For Breast Cancer

  2008cites this paper
• Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods.

  2007influential citation
• Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study

  2007cites this paper
• Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression.

  2007cites this paper
• The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature

  2007cites this paper
• Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR.

  2007cites this paper
• Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu

  2007cites this paper
• Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system.

  2007cites this paper
• Targeted therapy of breast cancer.

  2007cites this paper